FARE has been monitoring developments concerning the Auvi-Q® epinephrine auto-injector, which was recalled last fall. On Feb. 23, 2016, Sanofi US announced that the license and development agreement between Sanofi and kaléo, the developer of Auvi-Q, will terminate later this year. At that time, all U.S. and Canadian rights will be returned to kaléo.
According to a press release from Sanofi, kaléo will evaluate timing and options for bringing Auvi-Q back to market.
FARE will continue to closely monitor and work to ensure that the patient community’s voice is part of this evaluation. FARE believes that all individuals with food allergies should have affordable access to life-saving epinephrine. Epinephrine is the only medication that can reverse the symptoms of a severe life-threating allergic reaction, known as anaphylaxis.
Sanofi US will complete and return the reimbursement process associated with the Oct. 28, 2015, voluntary nationwide recall of Auvi-Q.
For more information regarding the recall process, please refer to Auvi-Q.com. For the full press release from Sanofi, please click here.